{"id":75276,"date":"2025-12-31T11:12:09","date_gmt":"2025-12-31T11:12:09","guid":{"rendered":"https:\/\/www.europesays.com\/ee\/75276\/"},"modified":"2025-12-31T11:12:09","modified_gmt":"2025-12-31T11:12:09","slug":"uuring-multiskleroosi-on-kahte-tuupi-tervis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ee\/75276\/","title":{"rendered":"Uuring: multiskleroosi on kahte t\u00fc\u00fcpi | Tervis"},"content":{"rendered":"<p>Sclerosis multiplex&#8217;i ehk hulgiskleroosi on kahte t\u00fc\u00fcpi, osutab uus rahvusvaheline <a href=\"https:\/\/academic.oup.com\/brain\/article\/148\/12\/4578\/8321558\" rel=\"nofollow noopener\" target=\"_blank\">uuring<\/a>. Tehisaru toel tehtud avastus v\u00f5ib viia tulevikus patsientide t\u00e4psema ja sobivama ravini.<\/p>\n<p>Multiskleroosiga (MS) elab \u00fcle maailma miljoneid inimesi. Praegu m\u00e4\u00e4ratakse neile ravi eesk\u00e4tt s\u00fcmptomite p\u00f5hjal. See aga t\u00e4hendab, et ravi ei pruugi alati toimida, sest see ei arvesta piisavalt patsiendi ega tema haiguse bioloogiliste ise\u00e4rasustega. N\u00fc\u00fcd tuvastas University College Londoni teadlaste juhitud t\u00f6\u00f6r\u00fchm, et bioloogilises m\u00f5ttes jaguneb MS kaheks haruks, vahendab <a href=\"https:\/\/www.theguardian.com\/society\/2025\/dec\/30\/two-new-subtypes-of-ms-found-in-exciting-breakthrough\" target=\"_blank\" rel=\"noopener nofollow\">The Guardian<\/a>.<\/p>\n<p>\u00dcks valk m\u00e4\u00e4rab palju<\/p>\n<p>Uuringu autorid vaatasid l\u00e4bi 600 patsiendi vereproovid. Lisaks v\u00f5tsid nad appi tehisaru ja magnetresonantstomograafilise (MRT) aju-uuringu. Esmalt m\u00f5\u00f5tsid nad patsientide veres leiduva spetsiifilise valgu \u2013 neurofilamendi kergahela (sNfL) \u2013 taset. See valk toimib biomarkerina, mis v\u00f5ib viidata n\u00e4rvirakkude kahjustustele juba varajases staadiumis ja anda aimu, kui aktiivselt haigus kehas toimetab.<\/p>\n<p>J\u00e4rgmiseks s\u00f6\u00f6tis t\u00f6\u00f6r\u00fchm vereproovide koostise andmed ja patsientide ajust tehtud \u00fclesv\u00f5tted SuStaIn-nimelisele masin\u00f5ppe mudelile. Tehisaru antud tulemustest ilmnes, et multiskleroos jaguneb selgelt kaheks: varajase sNfL-i ja hilise sNfL-i t\u00fc\u00fcbiks.<\/p>\n<p>Esimese t\u00fc\u00fcbi korral leidus sNfL valku patsientide veres rohkelt juba haiguse varajases staadiumis. \u00dchtlasi oli selle t\u00fc\u00fcbi patsientidel n\u00e4ha ajus m\u00f5hnkehas kahjustusi ja samuti tekkisid neil kiiremini uued ajukahjustuskolded. Teadlaste hinnangul viitab see haiguse agressiivsemale ja aktiivsemale vormile.<\/p>\n<p>Teise t\u00fc\u00fcbi patsientidel t\u00e4heldasid aju kudede k\u00f5hetumist sellistes piirkondades nagu limbilises koores ja s\u00fcgaval paiknevas hallaines. Alles seej\u00e4rel suurenes nende veres sNfL valgu sisaldus. T\u00f6\u00f6r\u00fchma s\u00f5nul paistab sellist t\u00fc\u00fcpi MS kulgevat aeglasemalt ja p\u00f5hjustavat silmn\u00e4htavat kahju hiljem.<\/p>\n<p>Praegusest isiklikum ravi?<\/p>\n<p>Uuringu autorite s\u00f5nul aitab nende leid arstidel edaspidi paremini aru saada, milliseid patsiente millised t\u00fcsistused rohkem ohustavad. Seel\u00e4bi saaksid arstid multiskleroosi ravi m\u00e4\u00e4rates arvestada tulevikus rohkem patsientide erip\u00e4radega.<\/p>\n<p>Uuringu juhtivautori ja University College Londoni teaduri Arman Eshaghi s\u00f5nul pole MS \u00fcks kindlapiiriline haigus. Praegused MS-i liigituss\u00fcsteemid ei kirjelda tema hinnangul haigusest tingitud koemuutusi piisavalt h\u00e4sti. Koos kolleegidega kirjeldas ta n\u00fc\u00fcd enda s\u00f5nul esimest korda haigusel kahte selgesti eristuvat bioloogilist mustrit.<\/p>\n<p>Eshaghi s\u00f5nul saaks tehisaru t\u00f6\u00f6riista abil teha edaspidi iga patsiendi puhul kindlaks, millist t\u00fc\u00fcpi multiskleroos kellelgi on. See t\u00e4hendaks, et varajase sNfL-i t\u00fc\u00fcpi haigusega patsiendid peaksid saama t\u00f5husamat ravi ja arstid nende k\u00e4ek\u00e4iku hoolsamalt j\u00e4lgima. Seevastu hilise sNfL-i t\u00fc\u00fcpi haigusega patsientidele v\u00f5iks pakkuda teistsugust ravi: n\u00e4iteks ajurakke kaitsvaid n-\u00f6 r\u00e4tsepat\u00f6\u00f6na sihitud teraapiaid.\u00a0<\/p>\n<p>Praegu on multiskleroosi \u00e4genemistega patsientidele saadaval paark\u00fcmmend raviv\u00f5imalust. Ehkki esimesed p\u00e4\u00e4sukesed on olemas ka s\u00fcveneva haigusega patsientide raviks, on v\u00f5imalusi selles vallas veel v\u00e4he.\u00a0<\/p>\n<p>Uuringuga mitte seotud heategevusorganisatsiooni MS Society k\u00f5neisiku Caitlin Astbury s\u00f5nul aitab haiguse parem m\u00f5istmine t\u00f5en\u00e4olisemalt patsientidel selle progresseerumisele pidurit t\u00f5mmata. Uuring lisab kaalu \u00fcha enam levivale seisukohale, et hulgiskleroosi kirjeldades tuleks loobuda senistest liigitustest nagu &#8220;\u00e4genemistega kulgev&#8221; v\u00f5i &#8220;progresseeruv&#8221;. Selle asemel tuleks liikuda m\u00f5istete suunas, mis peegeldavad haiguse tegelikku bioloogilist olemust.\u00a0<\/p>\n<p>Uuring avaldati ajakirjas <a href=\"https:\/\/academic.oup.com\/brain\/article\/148\/12\/4578\/8321558\" target=\"_blank\" rel=\"noopener nofollow\">Brain<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Sclerosis multiplex&#8217;i ehk hulgiskleroosi on kahte t\u00fc\u00fcpi, osutab uus rahvusvaheline uuring. Tehisaru toel tehtud avastus v\u00f5ib viia tulevikus&hellip;\n","protected":false},"author":2,"featured_media":75277,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[6601,26,27,37,33,35,34,36,31,32,21,22721,28,29,38114,38117,38118,19,25,38115,38116,23,24,22,20,38113,30],"class_list":{"0":"post-75276","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-uldised-uudised","8":"tag-aju","9":"tag-breaking-news","10":"tag-breakingnews","11":"tag-ee","12":"tag-eesti","13":"tag-eesti-keel","14":"tag-estonia","15":"tag-estonian","16":"tag-featured-news","17":"tag-featurednews","18":"tag-headlines","19":"tag-hulgiskleroos","20":"tag-latest-news","21":"tag-latestnews","22":"tag-ms","23":"tag-multiskleroos","24":"tag-neroloogia","25":"tag-news","26":"tag-populaarseimad-lood","27":"tag-sclerosis-multiplex","28":"tag-sm","29":"tag-top-stories","30":"tag-topstories","31":"tag-uldised-uudised","32":"tag-uudised","33":"tag-vereproov","34":"tag-viimased-uudised"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ee\/115813885055909457","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/75276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/comments?post=75276"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/posts\/75276\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media\/75277"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/media?parent=75276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/categories?post=75276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ee\/wp-json\/wp\/v2\/tags?post=75276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}